Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 9/20 | 0.60 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.60 |
| ▸ | MLYCD | O95822 | 8/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | RORC | P51449 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6215194 | 0.81 | NR1H3 (0.58) | NR1H3NR1H2MLYCDSMN1; SMN2LMNA | |
| SCHEMBL6210996 | 0.80 | LMNA (0.55) | NR1H3NR1H2MLYCDSMN1; SMN2LMNA | |
| SCHEMBL14112771 | 0.78 | L3MBTL1 (0.44) | NR1H3NR1H2LMNA | |
| SCHEMBL6493549 | 0.77 | MLYCD (0.63) | NR1H3NR1H2MLYCDSMN1; SMN2LMNA | |
| SCHEMBL4628014 | 0.76 | NR1H3 (1.00) | NR1H3NR1H2MLYCDRORC | |
| SCHEMBL19822977 | 0.76 | SLC9A5 (0.40) | NR1H3NR1H2MLYCDLMNAMAPK1 | |
| SCHEMBL6214998 | 0.75 | LMNA (0.56) | NR1H3NR1H2MLYCDSMN1; SMN2LMNA | |
| SCHEMBL6485930 | 0.75 | LMNA (0.64) | NR1H3NR1H2MLYCDSMN1; SMN2LMNA | |
| SCHEMBL27294764 | 0.74 | L3MBTL1 (0.46) | SMN1; SMN2LMNAGAAMAPK1 | |
| SCHEMBL6212908 | 0.73 | MLYCD (0.55) | NR1H3NR1H2MLYCDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900244-B2 | Anilino liver X-receptor modulators | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | claimed |
| US-20040087632-A1 | Controlling metabolism of lipids, cholesterol | PHARMACIA CORPORATION | 2004-05-06 | — | — | US | claimed |
| US-6900244-B2 | Anilino liver X-receptor modulators | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040087632-A1 | Controlling metabolism of lipids, cholesterol | PHARMACIA CORPORATION | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087632-A1 | Controlling metabolism of lipids, cholesterol | NR1H2, NR1H3, SREBF1 | NR1H3 2/4885NR1H2 1/4885MLYCD 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.